Stephen L. Sazinsky

Medicine · Health Sciences

11h-index2.1kcitations20works4.72yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(9), Cancer Immunotherapy and Biomarkers(4), Glycosylation and Glycoproteins Research(4), Viral Infectious Diseases and Gene Expression in Insects(4), Immune cells in cancer(3)

Publications20 total

Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth
Cancers·2024Open Access
Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types
International Journal of Molecular Sciences·2024· 11 citedOpen Access
Streamlined Multi-Attribute Assessment of an Array of Clinical-Stage Antibodies: Relationship Between Degradation and Stability
Applied Spectroscopy·2024· 3 citedOpen Access
Abstract 5613: Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell <i>in vitro</i> assays and fresh human tumor cultures, and inhibits tumor growth in <i>in vivo</i> murine tumor models
Cancer Research·2022· 1 cited
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models
PLoS ONE·2020· 40 citedOpen Access
Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs
Journal of Molecular Biology·2017· 17 citedOpen Access
Abstract SY03-02: Preclinical assessment of JTX-2011, an agonist antibody targeting ICOS, supports evaluation in ICONIC clinical trial
Cancer Research·2017· 3 cited
Abstract 3842: Design and engineering of TRAIL fusion proteins for cancer therapy
Cancer Research·2016
Abstract 573: Preclinical evaluation of JTX-2011, an anti-ICOS agonist antibody
Cancer Research·2016· 1 cited
Comprehensive Experimental and Computational Analysis of Binding Energy Hot Spots at the NF-κB Essential Modulator/IKKβ Protein–Protein Interface
Journal of the American Chemical Society·2013· 47 citedOpen Access
Quantitative Analysis of Growth Factor Receptor Signaling
The FASEB Journal·2010
Rapid Evolution of Functional Complexity in a Domain Family
Science Signaling·2009· 53 cited
Directed evolution of a secretory leader for the improved expression of heterologous proteins and full‐length antibodies in <i>Saccharomyces cerevisiae</i>
Biotechnology and Bioengineering·2009· 192 citedOpen Access
Engineering aglycosylated antibody variants with immune effector functions
DSpace@MIT (Massachusetts Institute of Technology)·2009Open Access
Aglycosylated immunoglobulin G<sub>1</sub>variants productively engage activating Fc receptors
Proceedings of the National Academy of Sciences·2008· 175 citedOpen Access
A Specificity Map for the PDZ Domain Family
PLoS Biology·2008· 469 citedOpen Access
Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3
Protein Science·2007· 97 citedOpen Access
Isolating and engineering human antibodies using yeast surface display
Nature Protocols·2006· 937 cited
Chao, G. et al. Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 1, 755-768
2006· 2 cited
Stably folded de novo proteins from a designed combinatorial library
Protein Science·2003· 98 cited

Frequent Co-authors

K. Dane Wittrup(5), Sachdev S. Sidhu(3), Kutlu G. Elpek(3), Ellen Duong(3), Lindsey A. Shallberg(3), Matthew Wallace(3), Sriram Sathyanarayanan(3), Deborah Law(3), Jennifer S. Michaelson(3), Christopher J. Harvey(3), Mohammad Zafari(3), Jessica Ritter(3), Denise Manfra(3), Igor Feldman(3), Tatiana I. Novobrantseva(3), Ginger Chao(2), Wai Leung Lau(2), Benjamin J. Hackel(2), Shaun M. Lippow(2), Bridget Currell(2)